Inflammatory Skin Diseases Drug Market Size, Key Vendors, Growth Rate, Drivers, Volume & Forecast Report

Inflammatory Skin Diseases Drug Market

Summary

Latest Report Available at Analytical Research Cognizance Inflammatory Skin Diseases Drug Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.

Description

This report provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under development and key players involved in therapeutic development for acne vulgaris, rosacea and chronic urticaria (also known as hives). It also features dormant and discontinued products.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. There are 60 products in development for this indication, and companies operating in this space include Cassiopea and Elorac.

Access The Complet report @ http://www.arcognizance.com/report/inflammatory-skin-diseases-drug-development-pipeline-review-2018

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. There are 18 products in development for this indication, and companies operating in this space include Dermata Therapeutics and Promius Pharma.

Chronic urticaria, also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. There are 17 products in development for this indication, and companies operating in this space include GlaxoSmithKline and Novartis.

Molecular targets acted on by products in development for inflammatory skin disorders include cytokines, ribosomal RNA and retinoic acid receptors.

Request for sample copy of  report @ http://www.arcognizance.com/enquiry-sample/57274

Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies Mentioned:
3SBio Inc
Acne Vulgaris
BioPharmX Inc
Braintree Laboratories Inc
Cassiopea SpA
Cutanea Life Sciences Inc
Daewoong Co Ltd
Deltanoid Pharmaceuticals Inc
ELORAC Inc
Foamix Pharmaceuticals Ltd
Galderma SA
Helix BioMedix Inc
Innovation Pharmaceuticals Inc
Lee’s Pharmaceutical Holdings Ltd
LEO Pharma A/S
…..

Place a direct purchase order of  report at @ http://www.arcognizance.com/enquiry-before-buying/57274

Some Points Of TOC:

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 7
2.1 Inflammatory Skin Diseases Report Coverage 7
2.2 Acne Vulgaris – Overview 7
2.3 Rosacea – Overview 7
2.4 Chronic Urticaria Or Hives – Overview 7

3 Therapeutics Development 8
3.1 Acne Vulgaris 8
3.2 Rosacea 15
3.3 Chronic Urticaria Or Hives 19

4 Therapeutics Assessment 23
4.1 Acne Vulgaris 23
4.2 Rosacea 30
4.3 Chronic Urticaria Or Hives 38

5 Companies Involved in Therapeutics Development 45
5.1 Acne Vulgaris 45
5.2 Rosacea 61
5.3 Chronic Urticaria Or Hives 66

6 Dormant Projects 71
6.1 Acne Vulgaris 71
6.2 Rosacea 75
6.3 Chronic Urticaria Or Hives 76

7 Discontinued Products 77
7.1 Acne Vulgaris 77
7.2 Rosacea 77
7.3 Chronic Urticaria Or Hives 78

8 Product Development Milestones 79
8.1 Acne Vulgaris 79
8.2 Rosacea 90
8.3 Chronic Urticaria Or Hives 101

9 Appendix 112
9.1 Methodology 112
9.2 Coverage 112
9.3 Secondary Research 112
9.4 Primary Research 112
9.5 Expert Panel Validation 112
9.6 Contact Us 113
9.7 Disclaimer 113

About Us:

http://arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics” based on the data collection facilities of big data, the face of “business research facilities” has changed drastically  . With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “out of the box” developments in the market.

Contact Us:

Matt Wilson,

100 Church street, 8th floor,

Manhattan, New york, 10007

Phone No: +1 (646) 434-7969

Email: sales@arcognizance.com

Analytical Research Cognizance

About Analytical Research Cognizance

View all posts by Analytical Research Cognizance →